BPC-157 and TB-500 are both research peptides studied in tissue models, but they are different molecules. BPC-157 is a 15 amino acid fragment of a gastric protein; TB-500 is a synthetic fragment of thymosin beta-4, a 43 amino acid protein involved in actin regulation.
For research purposes only. Not for human consumption. This article is educational and references published laboratory research; it is not medical advice and does not describe an approved use of any compound.
BPC-157 and TB-500 are routinely mentioned in the same breath, which has produced a lot of confusion about what they actually are. They are unrelated molecules studied through different pathways. Here is the comparison Vitality Peps uses internally, restricted to what the literature supports.
Origin and structure
BPC-157 is a 15 amino acid synthetic peptide based on a sequence identified in gastric juice. TB-500 is a synthetic peptide corresponding to a short active region associated with thymosin beta-4, a protein present in most mammalian cell types.
Different length, different parent sequence, different research history. They are not variants of one another.
Pathways under investigation
BPC-157 research focuses largely on angiogenic signalling and cytoprotective effects in preclinical tissue models.
TB-500 research focuses on actin binding and cell migration, which is a mechanistically distinct route to a superficially similar research question.
Both bodies of work are preclinical. Neither has an established controlled human clinical evidence base.
Practical differences in the lab
- Both are supplied lyophilised and reconstituted with bacteriostatic water.
- BPC-157 is often described as comparatively stable in solution; TB-500 handling follows the same conservative refrigerated protocol.
- Vial masses differ, so concentration must be recalculated per compound rather than assumed. Use the reconstitution calculator.
- Batch documentation should be checked separately for each compound.
On combined protocols
Combination use is widely discussed in informal communities and thinly represented in peer reviewed literature. There is no controlled evidence establishing an interaction profile between the two in humans. Any protocol that presents one as standard is not reflecting the published record.
Research use only
Both compounds are supplied by Vitality Peps for in vitro laboratory research only. Not for human or veterinary consumption.
Frequently asked questions
What is the main difference between BPC-157 and TB-500?
Origin and size. BPC-157 is a short peptide derived from a gastric protective protein and is studied mainly in gut and connective tissue models. TB-500 is a fragment of thymosin beta-4, a protein that binds actin, and is studied in cell migration and vascular models. Their sequences, molecular weights and research questions differ.
Are BPC-157 and TB-500 used together in research?
Yes, combined protocols appear in preclinical literature and in commercial blends, on the reasoning that the two act through different pathways. The evidence for a combined effect comes from animal and cell studies; there are no controlled human trials of the combination.
Which one should a researcher choose?
It depends on the model and the question. Studies of gut lining, tendon or ligament tissue tend to use BPC-157; studies of cell migration, blood vessel formation or cardiac tissue tend to use TB-500 or thymosin beta-4. Both are research use only and neither is an approved medicine.
Do they differ in handling?
Both ship as lyophilised powder and are reconstituted with bacteriostatic water. TB-500 vials are commonly larger in milligram terms, so the solvent volume differs, but storage rules are the same: cold, dark, and refrigerated after reconstitution.
For research purposes only. Not for human consumption. This article is educational and references published laboratory research; it is not medical advice and does not describe an approved use of any compound.